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1. Introduction 
Abdominal aortic aneurysm (AAA) is a common life threatening condition in the western 
world. In England and Wales alone, over 2500 patients present to hospital with rupture of 
AAA annually, of whom over two thirds die of their condition1. The best treatment for AAA 
is elective repair of pre-symptomatic abdominal aortic aneurysms. Such a therapeutic 
strategy depends on effective identification of patients with AAA and the subgroup of 
patients in whom there is a real risk of aneurysm rupture. As the vast majority of patients 
with AAAs are asymptomatic, timely identification of AAA may be achieved through 
targeted screening of the at risk populations. Over the last two decades longitudinal studies 
of patients with smaller AAAs have provided insights into the timing of AAA repair and the 
need for and frequency of ultrasound surveillance if an expectant management strategy is 
followed. This chapter discusses the available evidence for screening for AAA as well as all 
the other measures which have helped to optimise therapeutic strategies in the management 
of patients with AAA throughout the patients’ journey from the initial diagnosis to the 
eventual repair of AAA.  
2. Targeted screening for AAA 
In the past 40 years with the advent and generalised use of abdominal ultrasonography 
there has been an accurate, cheap and non invasive tool for the diagnosis of abdominal 
aortic aneurysms. Abdominal ultrasonography has been found to be an accurate and 
reproducible modality in measuring the dimensions of AAA. This has led to the concept of 
its use for screening of at risk populations. In the last 20 years there have been four 
population based randomised controlled trials which have assessed the value of targeted 
screening in reducing mortality from abdominal aortic aneurysms in the unselected elderly 
male population2-5. These trials which have been undertaken in Chichester (England)2, 
England (MASS trial) 3, Viborg County (Denmark) 4 and the city of Perth and suburbs 
(Western Australia)5 have together recruited over 120,000 subjects. All of these studies have 
reported on long term (over 10 years) follow up. Using the predefined criteria set by the US 
Preventative Screening Task Force USPSTF 6 the MASS trial has been classified as good with 
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the other three trials classified as fair i.e. not meeting all the criteria but judged to have no 
fatal flaws7.  
The Chichester trial was the first to assess the value of screening for AAA in the at risk 
population. It was also unique as it included women as well as men. It identified all men 
and women aged between 65 and 80 years of age from 9 general practices in the catchment 
area of St Richard’s hospital in Chichester between 1988 and 19912,8,9. The subjects were 
randomised to undergo a single screening ultrasound (US) or a control group who were 
followed up. AAA rupture rates, aneurysm related mortality, and overall mortality was 
compared between the two groups. Upon identification of AAA the therapeutic strategy for 
AAAs with maximum diameters between 30-44mm was once yearly surveillance US, AAAs 
between 44 and 59mm underwent 3 monthly ultrasound scans, whilst aneurysms greater 
than 60mm in diameter were considered for repair2.8.9. Overall 6040 men were randomised, 
the authors reported a significant reduction in aneurysm related mortality which has been 
maintained over 15 years. However, to date this study has demonstrated no difference in the 
all cause mortality between the two groups. The Chichester trial has been criticized for its 
relative small size, a relatively high aneurysm diameter threshold for repair and including 
75-80 year old patients in whom the benefits of screening are marginal. In addition 27-
percent of subjects who were invited for screening refused to participate thereby diluting 
the benefits of screening. Despite these criticisms the Chichester study remains a land mark 
as it demonstrated the feasibility of US screening for AAA and its potential value and 
remains a blue print for other aneurysm screening studies. This study identified a low but 
none the less troubling rate of AAA rupture in patients who had a non aneurysmal aorta on 
the first screening study2. A population based screening study in Gloucester demonstrated 
that 2.2-percent of men aged 65-73 years have a maximal aortic diameter of 2.5 to 2.9 mm 
and suggested that this group of patients should undergo repeat US scanning at 5 yearly 
intervals10. 
The second RCT to study the value of population based screening for AAA was carried out 
in Viborg County of Denmark. In 1994 all men aged between 65 and 74 were randomised to 
either undergo a single screening US or the control group. In all 12639 patients were 
randomised4,11,12. This study reported a 66-percent reduction in the aneurysm related 
mortality which has been maintained over 14-years. In addition they reported a 2-percent 
reduction in overall mortality after long term follow-up which did not reach significance4.  
The Western Australia population based screening was a study of similar design. It 
randomised 41000 men between the ages of 65 and 85 years to a single US screening and a 
control groups. They reported no difference in aneurysm outcomes in the full study 
population but when the analysis was restricted to 65-74 year old men they reported a 
significant reduction in aneurysm related mortality after 5 years of follow-up5. Long term 
follow-up results of this study have not been published as a separate publication to date, 
however in a reply to a correspondence by Lederle, Norman and Lindholt did report a 
surprisingly high, 3-percent reduction in overall mortality in the restricted (65-74 year old) 
patient population after 10 years of follow-up from the Western Australia trial which was 
statistically significant13.  
The MASS trial which was a population based screening RCT for men aged between 65 and 
74 years of age included 4 screening centres in the United Kingdom. This study randomised 
67770 patients again to single screening ultrasound or a control group and was designed to 
study cost effectiveness of screening in addition to reductions aneurysm related and overall 
mortality3,14,15. This study reported a 48-percent relative risk reduction in aneurysm related 
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mortality as a result of screening. This benefit was present at 4 years 14 and was maintained 
at 10 years (Figure-1)3. There was a reduced AAA rupture rate in the patients who were 
invited for screening. Most of these ruptures occurred in patients who were excluded from 
the potential benefits of screening, such as patients who refused or did not attend screening, 
patients who were lost to follow-up and those who either refused or deemed not fit for 
surgery3. The MASS trial also reported a small rate of AAA rupture in patients who did not 
have an AAA on the screening scan, this rate was reported as 3 per 10,000 person years after 
10 years of follow up3. 
 
 
Fig. 1. Cumulative deaths related to abdominal aortic aneurysm, by time since 
randomisation (MASS Trial) 3. From: Thompson SG, Ashton HA, Gao L, Scott RA and 
Multicentre Aneurysm Screening Study Group, Screening men for abdominal aortic 
aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre 
Aneurysm Screening Study, BMJ 2009; 338: b2307. 
In addition to the above RCTs a number of systematic reviews and meta-analyses have 
attempted to assess the value of population based screening in the medium and long term. 
Cosford and Leng in a Cochrane systematic review reported that there was significant 
evidence of reduction in aneurysm related mortality from AAA in men aged 65 to 80 years 
who undergo population based ultrasound screening, but no significant reduction in all 
cause mortality16. This review was based on the 3-5 year follow up data from the above 
RCTs. Subsequent to this Norman and Lindholt published a meta-analysis which showed 
that population based AAA screening after 7-15 years of follow up resulted in a reduction of 
both AAA and all cause mortality17. Their findings were contested as the reported 3-percent 
all cause mortality reduction was larger than what was expected by an approximately 50-
percent reduction in aneurysm related mortality, bearing in mind that the mortality from 
AAA in the patient population is reported to be between 1.1 to 3-percent18.  
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Takagi et al. conducted a further meta-analysis of US screening in the male population over 
the age of 65years using long term 10 to 15 year follow up data from the RCTs. They 
reported an absolute risk reduction in aneurysm related mortality of 4 per 1000 subjects 
screened (Figure-2). They also revealed a strong trend towards a significant reduction in all 
cause mortality7. The latter finding was surprising for the reasons mentioned already. The 
authors hypothesized that screening may coincide with the asymptomatic at risk population 
for cardiovascular disease coming in contact with health care professionals and becoming 
aware of smoking risk, their blood pressure etc.  The resultant reduction in cardiovascular 
risk factors may be in part responsible for additional reduction in all cause mortality. Such a 
hypothesis opens the door to the possibility of risk factor alteration and institution of 
secondary prevention measures such as commencement of anti-platelet agents and statin 
therapy during screening programmes thereby increasing the value of the screening7.  
 
 
Fig. 2. Forrest Plot of illustrating the reduction in aneurysm related mortality (A) and the 
trend towards a reduction in overall mortality (B) as a result of population based screening 
of men between the ages of 65 and 80 years after 10 years of follow up7. 
From: Takagi H, Goto SN, Matsui M, Manabe H, Umemoto T. A further meta-analysis of 
population-based screening for abdominal aortic aneurysm. J Vasc Surg. 2010; 52(4):1103-8. 
Cost effectiveness of a population based screening programme is calculated by measuring the 
costs of ultrasound screening as well as the extra procedures and surveillance that is required 
for the screen identified AAA and subtracting them from the costs of treating ruptured AAA. 
It is expressed in cost per life year gained. As the survival advantage in terms of life year 
gained continues to increase with time, the cost effectiveness of screening continues to 
improve. A comprehensive analysis of costs of screening was performed by the MASS trial 
participants. They calculated the cost per life year gained to be £41,000 after 4 years14, £14,000 
after 7 years 15and £7600 after 10 years3. Using the estimated life span of men aged 65 years the 
cost per life year gained is estimated to be in the region of £2300, which is well below the 
guideline figure of £25,000 which is considered acceptable for the adaptation of new medical 
technologies and interventions in the National Health Service of the United Kingdom19. 
Lindholt et al. also performed a comprehensive cost analysis of population based AAA 
screening using data obtained from the Viborg trial. They reported cost per Quality 
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Adjusted Life Year (QALY) gained as a result of screening to be €179 albeit with relatively 
wide 95% confidence intervals (€-4083 to €4682) 4. Both of these values for costs of screening 
are much lower than the cost analysis carried out by the USPSTF using primarily economic 
modelling in 2003 and suggest that population based AAA screening in men is more cost 
effective than the initial assessments suggested20. 
The role of screening for AAA in women remains controversial. To date there is no evidence 
that screening for AAA in an unselected population of women is associated with a reduction 
even in aneurysm-related mortality. Scott and colleagues conducted the only RCT 
(Chichester trial) which studied the value of screening in women over the age of 65 in an 
unselected population (n=9342) 21. They reported the prevalence of AAA in women to be 1·3 
percent, with other authors reporting a similar rate of 0·7–1·3 percent in unselected 
populations22-24. Scott et al. did not demonstrate a difference in rupture rates between the 
women randomized to screening and control populations of women at 5- and 10-year 
follow-up21. They concluded that screening for women was neither clinically indicated nor 
economically viable21. This study was limited by high rate of non attendance of women for 
AAA screening which ranged between 27 and 42-percent depending on patients age. They 
screened an unselected population of women without consideration of risk factors for 
aneurysm disease and fitness for repair; consequently a large proportion of women who 
were found to have an AAA did not undergo aneurysm repair25. The UK Small Aneurysm 
Trial revealed that female sex was an independent risk factor for AAA rupture; the rupture 
rate in women was three times higher than that in men, despite a smaller initial AP 
diameter. Furthermore, mean AP diameter preceding rupture was significantly lower in 
women than men26. A number of other authors have reported a higher growth and rupture 
rate of AAA in women 27-33. A Finnish community-based follow-up study reported that the 
aortic diameter was less than 5·5 cm in 24 per cent of women with a ruptured AAA, 
compared with only 5 per cent of men21. In light of these findings the 6 cm cut off value for 
repair of AAA in Chichester trial may have been too large to prevent aneurysm rupture in a 
proportion of screened women thereby reducing the value of screening in women.  
For screening to be effective in reducing aneurysm-related mortality in women, it will need 
to be limited to high-risk women who are fit to undergo aneurysm repair22. There is 
increasing evidence that women with atherosclerotic disease are at significantly higher risk 
of developing AAA. Derubertis and colleagues22 reported that the prevalence of AAA in 
women with multiple (more than three) atherosclerotic risk factors was 6·4 per cent. When 
these findings are considered in conjunction with the increased growth rates of AAA26 and 
higher aneurysm rupture rate in women, screening in women with multiple risk factors for 
AAA may become clinically and economically viable34-36. 
3. Optimum therapeutic strategy for small AAAs 
Abdominal aortic aneurysms are treated in order to prevent rupture and the associated 
mortality. Aneurysm treatment has its own associated morbidity and mortality. Open 
surgical repair is an invasive procedure which is tolerated poorly by the subgroup of 
patients with multiple medical co-morbidities. Even endovascular repair cannot be 
accomplished without an obligatory complication rate as a result of the initial deployment 
of the stent graft, in addition to which a proportion of patients require secondary 
procedures necessary to address complications such as endoleaks, device migration and 
stent thrombosis requiring long term close surveillance37. A small proportion of patients 
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who have undergone endovascular repair (EVAR) succumb to rupture. Therefore the 
natural history of the AAA needs to be balanced against the risk associated with treatment.  
Aneurysm diameter is one variable which has been consistently associated with the risk of 
rupture and has therefore been used to stratify patients into risk categories which decides 
whether US based surveillance or intervention is required to repair the aneurysm. In 
patients who are entered into surveillance programmes the maximum diameter of the 
aneurysm is used to decide on the frequency of scanning. In case of aneurysms greater than 
5.5 cm there is consensus that risk of rupture mandates repair if the patient is fit to undergo 
the procedure. In the case of aneurysms less than 4.0 cm in diameter, most clinicians agree 
on a watchful waiting approach. The evidence for the optimum therapeutic strategy in the 
mid-sized aortic aneurysms (maximum diameter between 4.0 to 5.5 cm in diameter) has 
been strengthened by a number of randomised controlled trials in the last 20 years which 
have consolidated the modern management of AAA26,38-41.  
The UK small aneurysm trial (UKSAT) was a multicentre RCT which randomised 1090 
patients, who were diagnosed as having an AAA with maximum AP diameter of 4.0 to 
5.5cm and were deemed fit to undergo an open repair of AAA to either immediate open 
repair or 3 monthly ultrasound surveillance. They reported the rupture rate of these AAA in 
the surveillance group to be in the 1-percent per year. They did not find any significant 
difference in aneurysm related or all cause mortality between the two groups after a follow 
up period of 7 years (Figure-3)26. During the follow up period over two thirds of patients 
who were randomised to surveillance had undergone repair of their aneurysms based on 
clinical grounds. 26 Long term follow up data from the small aneurysm trial has confirmed 
the initial findings of the UKSAT38.  
 
 
Fig. 3. Kaplan-Meier survival curves comparing survival of patients with small abdominal 
aortic aneurysms randomised to ultrasound surveillance and early surgery from UK small 
aneurysm trial26. From: United Kingdom Small Aneurysm Trial Participants. Long-term 
outcomes of immediate repair compared with surveillance of small abdominal aortic 
aneurysms. Lancet 1998;352: 1649-55. 
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A number of years after the publication of the UKSAT, the Veterans Affairs Cooperative 
Study group published the Aneurysm Detection and Management ADAM study39. This 
study involved screening of 126,196 veterans aged between 50 and 79 years of age for AAA 
with a single abdominal US. Those with AAA measuring 4.0 to 5.4 cm in diameter were 
offered entry to the trial. In all, 1136 subjects were randomly assigned to undergo early 
elective repair or ultrasound surveillance. Annualized rupture rate in the surveillance arm 
of the study was 0.6-percent, with no difference in aneurysm related and overall mortality 
between the two arms of the study 39. In this study as in UKSAT the majority of patients in 
the surveillance arm of the study had undergone elective repair after 8 years of follow up 
based on clinical grounds (symptomatic aneurysm, growth to greater than 5.5cm in 
diameter or rapid expansion by greater than 1 cm per year) 39. Completion of these two 
landmark trials which utilised open elective repair coincided with the advent and 
generalised use of endovascular repair as a primary  modality treatment of AAA. This 
resulted in some authors questioning the validity of these landmark trials in the era of 
endovascular repair and suggested that as endovascular repair can be performed with 
significantly lower peri-procedural morbidity and mortality a policy of surveillance for 
smaller AAAs should be examined against endovascular repair. 
To date two randomised controlled trials (PIVOTAL40 and CAESAR41) have been conducted 
to compare early endovascular repair of small AAAs with ultrasound surveillance. The 
prerequisite for both studies was that the patients which were randomised had AAAs which 
were anatomically suitable for endovascular repair.   
The PIVOTAL trial which was published in 2010, randomised 728 patients with AAAs 
measuring 40 to 50 mm in diameter to ultrasound based surveillance or early 
endovascular repair40. The mean duration of follow up was 20 months (+/-12 months) 
they found no difference in all cause or aneurysm related mortality between the two 
groups 40. At the end of the relatively short follow up duration almost one third of 
patients who were in the surveillance group had undergone an aneurysm repair based on 
clinical grounds40. The other study of a similar design was the CAESAR trial which 
randomised 360 patients with AAAs measuring between 40 and 54 mm to early 
endovascular repair or a watchful waiting strategy. 41 After 54 months of follow up there 
was no significant difference in rupture rates, aneurysm related and overall mortality 
between the two groups (Figure-4). This study revealed that the probability of the patients 
in the surveillance arm of the study requiring delayed repair based on clinical grounds 
during the duration of follow up was 60-percent41. In addition they reported that 16.4-
percent of aneurysms which upon entry into the trial were suitable for endovascular 
repair will be no longer suitable for EVAR after 36 months41.  
A constant finding in these trials has been that a significant proportion of AAAs under 
ultrasonographic surveillance come to require repair within the duration of the study26,39. 
This, taken together with the low but present annual risk of rupture has lead to differing 
interpretations of the results of these trials with some authors still advocating in favour of 
early repair of small AAA using the justification that a policy of early EVAR is as safe as a 
policy of US Surveillance42. To date there is no objective data to recommend either open or 
endovascular repair of smaller AAAs over a policy of watchful waiting and US surveillance. 
A policy of early EVAR is associated with a risk of early and delayed complications and a 
need for secondary procedures, thus mandating the need for close surveillance in patients 
who undergo early EVAR. It is therefore unlikely that there will be an economic justification 
for early endovascular repair.   
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Fig. 4. Kaplan–Meier estimates of survival at 54 months from time of randomisation in 
EVAR versus Surveillance groups. P = 0.6. Numbers at risk are shown. CAESAR trial41. 
From:Cao P; DeRango P, Verzini F, Parlani G et al. Comparison of surveillance vs Aortic 
Endografting for Small Aneurysm Repair (CAESAR) trial: results of a randomised 
controlled trial. Eur J Vasc Endovasc Surg. 2011; 41(1): 13-25. 
4. Open versus endovascular repair of AAA 
Ever since its inception, EVAR has offered the promise of reducing the perioperative 
morbidity and mortality which has been associated with open elective repair. By the end of 
last century, data from EVAR registries such as RETA 43and EUROSTAR 44 suggested that 
endovascular repair, although safe was associated with an immediate complication rate in 
addition to events such as endoleak and device migration which mandate lifelong 
surveillance and in a group of patients re-intervention. As with any new or emerging 
technology or intervention the case for primacy of EVAR over open repair in terms of 
perioperative mortality rate, post operative complications and cost effectiveness needs to be 
made using good quality evidence. A number of trials with a similar design have been 
commissioned in order to compare the outcomes following EVAR and open repair of AAA 
in patients who are anatomically suitable to undergo endovascular repair and fit to undergo 
open repair. These include the Dutch Randomised Endovascular Aneurysm Management 
(DREAM) 45,46trial, EVAR-1 Trial (United Kingdom) 47, ACE trial (France) 48 and Open 
Versus Endovascular Repair (OVER) of abdominal aortic aneurysms trial (United States) 49. 
The DREAM trial which was the first to report its results enrolled 351 patients between 
November 2000 and December 2003 from 24 centres in the Netherlands and 4 centres in 
Belgium. This study focused on short term combined mortality and morbidity outcomes45. It 
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reported a significantly lower operative mortality and severe complication rates in the 
EVAR group compared to the patients who had been randomised to open repair. At 2 years 
follow up aneurysm related mortality following EVAR was still significantly lower than 
open repair (2.1% versus 5.7%) however after 2 years of follow up there was no significant 
difference in the overall survival rates or freedom from moderate to severe complications 
between the two groups. The conclusions drawn from this trial was that there was a 
significant reduction in early morbidity and mortality following EVAR compared to open 
aneurysm repair but this difference is not sustained past 2 years45,46. 
EVAR-1 trial was a multicentre RCT which was conducted in 37 hospitals in the UK. It 
randomised 1252 patients with large AAA to either open or endovascular repair. Unlike the 
DREAM trial, EVAR-1 was designed to perform a comparison of long term survival, graft 
durability, quality of life and hospital costs associated with open repair and EVAR in 
addition to comparing short term mortality and morbidity between the two groups47.  They 
reported a significantly lower in perioperative morbidity and mortality following EVAR. 
Four years after randomisation, all cause mortality was similar between the two groups, 
although there was a persistent reduction in aneurysm related mortality in the EVAR 
group,(Figure-5)47. After 12 months there was no difference in quality of life scores between 
the two groups with a greater number of complications and re-interventions at 4 years in the 
EVAR arm of the study. The hospital costs of EVAR were 25-percent higher than open 
repair47. 
 
 
Fig. 5. EVAR-1 Kaplan-Meier survival curves comparing aneurysm related and overall 
mortality between patients who have been randomised to open elective and endovascular 
(EVAR) repair of AAA (EVAR-1 trial)47. From: EVAR trial participants. Endovascular 
aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 
1): randomised controlled trial. Lancet 2005; 365(9478): 2179-86. 
The OVER trial is a RCT which included 42 Veterans Affairs medical centres in the United 
States. It randomised 881 patients who had AAA with a greater than 50 mm in maximal 
diameter, an iliac aneurysm greater than 30mm in diameter or rapid sac expansion, to 
elective open repair or EVAR. The preliminary results from this study indicated that the 
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EVAR group had significantly lower 30-day mortality as well as all cause mortality49. After a 
mean follow up of 1.8 years the complication rate was not significantly different between the 
two groups nor was the secondary reintervention rate. As in the DREAM trial, the 
reintervention following EVAR was mainly due to a device related complications whereas 
the commonest reason for reintervention following open repair was for incisional hernia46,49. 
Early results from the ACE trial suggest similar early mortality benefit following 
endovascular repair which is lost after medium term follow up48. 
Some subgroups of patients such as those who have significant co-morbidities such as 
cardiovascular or respiratory disease, octogenarians and women with AAA, require an 
individualised approach and revised criteria for the management of AAA. From its 
inception EVAR has provided the promise of repairing AAA in patients in whom open 
repair poses a high risk. Therefore armed with the knowledge that smaller AAAs are best 
managed by a policy of watchful waiting, EVAR appeared to be an ideal modality for the 
management of patients with larger AAAs which are anatomically suitable for endovascular 
repair, have a reasonable predicted longevity but are unfit to undergo open repair. The 
EVAR-2 trial was designed to answer this question. EVAR-2 trial was a randomised 
controlled trial of 338 patients who had an AAA with a maximum diameter of greater than 
5.5cm and their aneurysm morphology was anatomically suitable for EVAR, but were 
medically unsuitable to undergo open repair. Primary endpoint was all-cause mortality, 
with secondary endpoints of aneurysm-related mortality, health-related quality of life, 
postoperative complications, and hospital costs50. 
The 30-day operative mortality in the EVAR group was 9.0-percent and the no intervention 
group had an annual rupture rate of 9·0-percent per year. Aneurysm related mortality in the 
patient population was 13-percent and all cause mortality after 4 years of follow up was 64-
percent 50.  
 
 
Fig. 6. Kaplan-Meier curves comparing aneurysm related and overall mortality between 
patients who have been randomised to EVAR and no intervention group (EVAR-2 trial)50. 
From: EVAR trial participants. Endovascular aneurysm repair and outcome in patients unfit 
for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. 
Lancet 2005; 365(9478): 2187–92. 
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There was no significant difference in all-cause mortality between the EVAR group and the 
no intervention group (hazard ratio 1·21, 95% CI 0·87–1·69). There was no difference in 
aneurysm-related mortality (Figure-6) 50. A policy of early endovascular repair was 
significantly more expensive than expectant management and was associated with a higher 
complication and reintervention rate. There was no difference in quality of life scores 
between the two arms of the study50. Therefore the conclusion drawn by the authors was 
that this population of patients are best served by conservative treatment. Clearly the design 
of such a study provides one difficulty and that is the definition of not fit for open AAA 
repair is subject to clinical opinion and may be related to factors that do not affect patient’s 
longevity. The other group of patients are those with one organ morbidity such as 
respiratory disease or border line medical fitness, who have a large AAA and favourable 
anatomy for endovascular repair. Therefore clinical judgement is exercised in the 
application of results of EVAR-2 trial.  
5. Medical treatment of patients with AAA 
In addition to risk of growth and rupture, patients with AAA are at risk from other 
cardiovascular events by the virtue of their age, medical co-morbidities and male 
preponderance of AAA. Medical management of patients with known AAA follows two 
parallel but different aims, reducing cardiovascular event rates perioperatively and during 
follow up in addition to aneurysm specific therapy which is aimed at slowing aneurysm 
growth and reducing the risk of rupture51-53. 
Hyperlipidaemia, a known modifiable risk factor in the development of cardio-vascular 
disease, can be treated with the use of drugs such as the statins (3-hydroxyl-3-
methylglutaryl coenzyme A reductase inhibitors). Patients with AAA are known to be at 
high risk of cardio-vascular disease as well as increased risk of cardio-vascular 
complications following AAA repair 54. Statin therapy has been associated with improved 
survival due to decreased risk of cardio-vascular complications, in both open and 
endovascular repair 54-58.  Although the primary mechanism of statins is in reducing low 
density lipoproteins and total cholesterol levels along with increasing levels of high density 
lipoproteins, other protective non lipid mechanism may be at work. These so called 
pleiotropic effects describe a diversity of cellular events which have an effect on several 
components of the arterial wall, including: endothelial cells; smooth muscle cells; platelet 
function, monocytes and macrophages, which together help to modify the inflammatory 
process in the vessel wall. Statins have been shown to be beneficial in the secondary 
prevention of coronary heart disease even in those patients with normal lipid profiles59-60. 
Matrix Metallo Proteinase-9 (MMP-9) expression is closely linked to aneurysm formation in 
animal models. In vitro experiments have shown that addition of Cerivstatins to human 
organ cultures from AAA reduces tissue levels of both total and active MMP-9 in a 
concentration dependent manner. Evans et al reported significantly reduced MMP-9 levels 
in excised tissue obtained from the aneurysm sac at the time of the aneurysm repair in 
patients who had been started on statins 3-weeks preoperatively compared with controls59. 
Schouten et al monitored 150 patients with small AAAs for 12 months and reported a 
reduction in the aneurysm expansion rate in patients receiving statin therapy60. In an 
observational study of 130 patients under surveillance, Sukhija reported no aneurysm 
expansion in 75 patients who were on statin therapy over a 2 year follow up period61. 
Schlosser et al in an analysis of the results of a large observational cohort study which 
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involved 5057 patients with vascular disease (Second Manifestation of ARTerial disease 
(SMART) study) and included 230 patients with small AAA revealed an independent 
association between statin therapy and reduced aneurysm growth rate. This reduced growth 
and rupture rates were independent of serum lipid values62,63.  
Over the years there has been some interest in β-blockers, both to slow the growth rate of 
AAA and to reduce perioperative morbidity form cardiovascular events. The benefit was 
postulated partly due to their haemodynamic properties and partly due to the effect of β-
blockers on matrix proteins. In a trial reported by Lindholt and colleagues the use of 
Propranolol did not reduce the rate of expansion of AAA, admittedly in the treatment arm 
of the study the compliance was poor with only 22-percent continuing on Propranolol by 2-
years64. Another trial which was carried out in Canada came to a similar conclusion owing 
to poor patient compliance in the treatment arm of the study65.   
In the last 15 years there has been significant interest in using peri-operative β-blockade as a 
means of increasing myocardial oxygen delivery thereby reducing the risk of perioperative 
myocardial infarction and death.  Mangano et al randomised 200 patients who were 
undergoing major elective non-cardiac surgery to either receive Atenolol or placebo. This 
was started before the induction of anaesthesia. Patients with evidence of congestive cardiac 
failure, systolic blood pressure of less than 100mmHg orpulse rate of less than 55 beats 
/minute, 3rd degree heart block or broncho-spasm were excluded. This treatment was 
continued for 6 months postoperatively. They reported a significant reduction in 
cardiovascular event rate and death from cardiac causes66. 
Poldermans and colleagues performed a similar study in patients undergoing elective 
aneurysm or infrainguinal arterial reconstruction. They screened 1351 patients for cardiac 
disease using Dobutamine stress testing, 173 patients had a positive test of whom 59 were 
randomised to receive Bisoprolol and 53 placebo67.  They also reported a significant 
reduction in non fatal cardiac events as well as cardiac death. In these patients β-blockade 
was started at least a week in advance of the operation and they were screened for 
bradycardia and hypotension preoperatively67.  
POISE was a large international randomised controlled trial of the use of extended release 
Metoprolol in patients undergoing non-cardiac surgery, the study randomised 8351 patients 
to either receive Metoprolol or placebo which was started 2-4 hrs before surgery and 
continued for 30 days. They reported a significantly reduced risk of myocardial infarction in 
the Metoprolol group but at the expense of higher mortality and stroke rate in the treatment 
arm of the study68. Similarly, Yang et al randomised such patients undergoing major 
vascular surgery, not already β-blocked, to dose adjusted Metoprolol or placebo 2 hours 
prior to surgery and until discharge or maximum of 5 post-operative days, and found no 
protective effects of β-blockade in terms of 30 day myocardial infarction and death rates69. β-
blockade did result in significantly more episodes of bradycardia and hypotension. In light 
of these findings the American Heart Association guidelines regarding perioperative β-
blocker therapy in patients undergoing non cardiac surgery have been altered to be more 
cautious and circumspective (Table-)70. 
In a large observational study, Hackham et al have shown that the use of Angiotensin 
Converting Enzyme Inhibitor (ACEI) therapy taken 3-12 months prior to data analysis 
significantly reduced the risk of rupture from AAA, independently of blood pressure71. This 
data was obtained from a large administrative database of 3379 patients with ruptured and 
11947 with non ruptured AAA. Other anti-hypertensive medications had no such effect 71. 
Interestingly, patients who had stopped ACEI therapy prior to admission were more likely 
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to present with ruptured AAA 71. The effect of ACEI on expansion of AAA is still equivocal, 
with some studies demonstrating no protective effect of ACEI therapy 72-73. Thompson et al 
in a recent observational study of 1269 patients with small AAA who were followed up for a 
mean of 3.4 years, reported a significant reduction in aneurysm growth rate as a result of 
ACE inhibitor therapy72. The follow up data from UK small aneurysm trial does not support 
the above finding74. 
Infection with Chlamydiae pneumonia has been postulated as a risk factor for AAA 
expansion, as the organism has been isolated from atherosclerotic plaque and the walls of 
AAA 75,76. Three small trials have aimed to elucidate the effect of the antibiotics Doxycycline 
and Roxithromycin in AAA growth, two of which have shown reduced aortic expansion 
associated with treatment 77,78, whilst another one by Baxter and colleagues showed no effect 
of doxycycline on aortic diameter 79. These three trials were limited by their small numbers. 
In addition administration of Doxycycline has been shown to suppress MMP-9 in both 
human and animal studies 79-81, suggesting that the reduction in aneurysm expansion rate 
with administration Doxycycline may be mediated through a mechanism which is 
independent from treatment of Chlamydiae pneumoniae infection. 
To date there is no conclusive evidence that any medical therapy is associated with a 
reduction in aneurysm growth or risk of rupture. However diagnosis of AAA provides a 
forum for instituting appropriate secondary prevention therapies, which will reduce 
morbidity and mortality in the peri-operative period as well reduce long term cardio-
vascular risk. There is some evidence that instituting some of these treatments such as statin 
therapy, ACE inhibitors may well have an effect on aneurysm growth and rupture rates.  
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